Hexis Lab is a technology company working at the forefront of raw material innovation. Hexis Lab produce ground-breaking ethnically targeted skincare products to protect and repair sun-damaged skin and improve life well-being. The company's discovery platform utilizes big data cloud computing approaches and in-silico computer modelling to screen a huge database of natural plant derived compounds for activity against our selected cellular targets.
Operator of a material innovation company intended to develop a thin bio-plastic coating for paper and card that replaces fossil fuel plastics in packaging for food, drink, cosmetics, and personal care. The company's coating is made from renewable feedstocks, particularly compostable seaweed, and marine-safe, paper and card packaging coated with biomaterial has been certified recyclable, enabling users to eliminate the need for single-use plastics.
EnsiliTech is a biopharmaceuticals company that preserves the integrity of vaccines and other biological materials.
aTen Therapeutics is a biotechnology company focused on developing innovative therapeutic antibodies aimed at treating major diseases, particularly cancer. The company's unique approaches target a fundamental control pathway associated with various diseases, enabling the development of treatments that can significantly improve patient outcomes. aTen Therapeutics' antibodies are designed to inhibit cancer cell growth, invasion, and metastasis across multiple tumor models. By combining these antibodies with anti-cancer agents, the company seeks to enhance the efficacy of cancer treatments and provide healthcare professionals with effective tools to improve the lives of cancer patients while protecting against the progression of metastases. The management team possesses extensive experience in the biopharmaceutical industry, emphasizing the company's commitment to advancing medical science and patient care.
Stemnovate Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. It specializes in providing innovative tools and technologies for drug screening and safety testing. The company offers a range of products, including induced pluripotent stem cells, primary human and multispecies cells, and a comprehensive cell culture and analysis package. Stemnovate's project, "Liver on chip," focuses on liver toxicity testing and incorporates advanced techniques in cellular reprogramming and organ-on-chip technology. The company also provides services such as cell reprogramming, differentiation, and application development. Its clientele includes pharmacists, contract research organizations, small to medium enterprises, and academic institutions, enabling researchers to overcome challenges associated with traditional mammalian cell lines in drug discovery.
Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.
NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and motor neurone disease. Founded in 2018 by a team of experienced biotech and pharmaceutical industry professionals, with a background in neuroscience drug discovery, NRG Therapeutics will initially focus on the discovery and development of brain penetrant mitochondrial permeability transition pore inhibitors for the treatment of Parkinson’s disease.
Better Nature Ltd. is a UK-based company specializing in the production of packaged organic food products, primarily focusing on tempeh and related items. Founded in 2018, the company offers a range of products including tempeh, tempeh mince, rashers, and smoked varieties, which are available through its online platform and various retailers. Better Nature is recognized as a pioneer in tempeh fermentation and innovation, utilizing proprietary starter cultures and processing methods to create high-protein, plant-based foods that are both nutritious and easy to prepare. The company has received several accolades for its innovative approach, including multiple awards at international food tech competitions. Better Nature has established a presence in over 200 independent retailers and is negotiating with major supermarkets in the UK. Additionally, the brand has gained recognition as a leading vegetarian protein provider on platforms like Amazon UK and has recently expanded into foodservice distribution. The company aims to offer products that promote health and sustainability, aligning with its mission to create food that benefits both people and the planet.
Biotangents Ltd., founded in 2015 and based in Glasgow, United Kingdom, specializes in designing and building biological pathways for the production of valuable natural materials. The company utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from various DNA components. Among its innovations is the development of terpenoid biosynthesis strains and the Short Sequence Randomisation technology for DNA randomisation. Biotangents has also conceptualized Moduleic Sensing, a modular cell-free nucleic acid detection technology, which led to the creation of a diagnostic test for identifying infectious diseases in livestock. This veterinary diagnostic device employs isothermal amplification technology, enabling precise detection without significant technical demands and allowing for quick adaptation to new targets. The solutions provided by Biotangents aim to mitigate the impact of infectious diseases in livestock, thereby enhancing the efficiency of animal protein production.
STORM Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Founded in 2015 and formerly known as Iceni Therapeutics Limited, the company utilizes a drug discovery and RNA analytics platform to identify novel targets and first-in-class drug candidates. By modulating RNA-modifying enzymes, STORM Therapeutics aims to address a range of diseases, including oncology, inflammation, viral infections, and central nervous system disorders. The company's innovative approach seeks to provide physicians with effective therapies targeting RNA epigenetic mechanisms.
We care about sustainability when growers get better yields worldwide. That's why we have developed Petiole - a mobile-first digital tool to boost agriculture productivity and science. Our mobile application is a time & money saver for agronomists, farmers and agscientists who track the plant growth via efficient leaf area measurements.
Kynos Therapeutics develops KMO inhibitors across key indications in inflammation, immunity, and metabolism.
BioStress Lab is revolutionizing the understanding and management of workplace stress. Using discreet biometric devices to objectively monitor workplace stress we make improvements to wellbeing and performance
PheroSyn specializes in the development and production of innovative pest pheromones aimed at enhancing agricultural practices. A spin-out from Rothamsted Research, a prominent non-profit research center, PheroSyn focuses on creating pheromone-based integrated pesticides. These products utilize pheromone traps to effectively attract specific pest species, allowing farmers to monitor pest infestations accurately. By providing clear indicators of pest presence, PheroSyn's solutions help farmers minimize unnecessary over-spraying, thereby improving cost efficiency and optimizing resource utilization. The company's approach contributes to more sustainable agricultural practices, benefiting farmers and society as a whole.
Drone Ag is a UK-based company focused on enhancing agricultural productivity through drone automation and artificial intelligence software. The team comprises farmers, agronomists, drone pilots, and software engineers who leverage their extensive experience from operating drone systems on their own 6,000-acre farm. The company offers a range of services, including drone training courses and user-friendly software solutions. By collecting and analyzing leaf-level crop data, Drone Ag enables farmers to optimize the application of resources, guiding ground machinery and drone sprayers to specific areas of fields at appropriate times. This practical approach to precision agriculture ensures that the company's offerings are grounded in real-world experience, allowing clients to improve their farming practices effectively.
Cytochroma manufacture genetically diverse stem cell-derived models to predict the safety and effect of drugs in a global population. Cytochroma’s automated cell manufacture, physiologically relevant models and rapid screening platform makes preclinical testing faster, safer and smarter.
Dyneval specializes in portable technology for cattle semen analysis, focusing on the precise measurement of semen quality. Its innovative technology assesses semen motility under quasi-in-vivo conditions, providing valuable insights into spermatozoa behavior. By utilizing dynescan data, Dyneval aids in informing breeding plans and confirming semen quality throughout the supply chain. This approach not only enhances livestock production but also contributes to improved food security and reduced methane emissions, allowing farmers to address issues related to poor conception rates effectively.
PheroSyn specializes in the development and production of innovative pest pheromones aimed at enhancing agricultural practices. A spin-out from Rothamsted Research, a prominent non-profit research center, PheroSyn focuses on creating pheromone-based integrated pesticides. These products utilize pheromone traps to effectively attract specific pest species, allowing farmers to monitor pest infestations accurately. By providing clear indicators of pest presence, PheroSyn's solutions help farmers minimize unnecessary over-spraying, thereby improving cost efficiency and optimizing resource utilization. The company's approach contributes to more sustainable agricultural practices, benefiting farmers and society as a whole.
Rinri Therapeutics is a provider of private biotechnology services intended to develop advanced regenerative stem cell-based therapies for the treatment of hearing loss. The company's stem cell technology replaces damaged or dead sensory cells of the inner ear, enabling doctors to restore hearing of patients.
AgPlus Diagnostics Ltd. is a company specializing in the development of a diagnostic platform technology aimed at providing quantitative point-of-care products for various clinical applications, including human and veterinary diagnostics. Established in 2009 and headquartered in Sharnbrook, United Kingdom, the company designs, manufactures, and supplies diagnostic tests and accompanying readers. AgPlus Diagnostics employs an electrochemical reader and measurement system that enables personalized healthcare by delivering rapid diagnostic results based on individual biomarker profiles. This technology allows healthcare providers to make critical treatment decisions in a matter of minutes, enhancing the efficiency of patient care.
Arecor Limited is a biopharmaceutical company based in Cambridge, United Kingdom, specializing in the development of innovative stabilization technology solutions for pharmaceutical and biotech firms. The company partners with these organizations to enhance the commercial value and utility of proteins used in various applications, including vaccines, therapeutic proteins, and treatments for complex diseases. Arecor focuses on developing products for areas such as diabetes, oncology, immunology, and infectious diseases, working to reformulate existing therapies to improve their efficacy and ease of use. Its innovative formulation technology enables high concentrations of antibodies for at-home self-administration and stable liquid formulations for biological therapies. Arecor also addresses challenges related to protein degradation and stability, particularly in the formulation of growth hormones and vaccines. Founded in 2006, Arecor operates primarily in the UK and has a global reach, collaborating with leading pharmaceutical and biotech companies to deliver enhanced therapeutic solutions.
CN Bio Innovations Ltd, based in Cambridge, United Kingdom, specializes in developing Organ-on-Chip devices aimed at enhancing preclinical drug testing for pharmaceutical and biotechnology companies. The company creates microphysiological systems and consumables that enable consumer goods and chemical firms to assess the toxicity and safety of novel compounds using in vitro studies across various biological processes, including oncology, infectious diseases, metabolism, and inflammation. Formerly known as Zyoxel Ltd, CN Bio is recognized for its proprietary LiverChip® platform, which features a full viral lifecycle model of hepatitis B, called Quantum-B®. This model is utilized in drug discovery and research partnerships with leading industry players. Collaborating with academic experts in bio-engineering and supported by grants from organizations such as the United States Defence Advanced Research Projects Agency and the UK Technology Strategy Board, CN Bio is committed to advancing next-generation organ-on-chip technologies to facilitate the development of innovative therapies that could improve global health outcomes.
Aramune Technologies is developing natural, plant derived feed materials which can be mixed with standard animal feeds to replace antimicrobial agents and promote growth.
Developer of a seed enhancement technology designed to reduce seed losses that make it hard for forestry organizations to meet government goals on tree planting. The company specializes in developing novel products that will significantly improve yield results in both the Forestry and the Agriculture sector, and technology coats seeds to absorb and retain moisture, enabling growers to increase seed germination in dry conditions.
Atelerix Limited provides storage and transportation of cells and tissues at room temperature. The company provides suspended cells, planted cells, and tissues. It also discovers and tests new drugs, develops cell therapies, and stores stem cells. The company was founded in 2006 and is based in Cambridge, United Kingdom.
BioFab is developing innovative new products for healthcare diagnostics with a particular focus on point-of-care testing (POCT) applications. Our vision is to create a truly universal diagnostic platform that can bring the clinical lab to the patient. Our innovative approach will enable this vision by offering a diverse range of test cartridges which can run on a single, universal reader device. It will not need any user training and will simply require the addition of the patient sample. Fully automated processing will then take place in a totally enclosed cartridge and will then deliver laboratory grade results without risk of cross-contamination. We are developing a test for Covid-19 with the support of an Innovate UK Smart award and will expand the product range to cover cardio-vascular disease, respiratory/gastric infections, blood infections (sepsis), STDs, Cancer and other conditions. We also have the ability to access the rapidly expanding Chinese market and have route-to-market and manufacturing base via established partners in China.
AgPlus Diagnostics Ltd. is a company specializing in the development of a diagnostic platform technology aimed at providing quantitative point-of-care products for various clinical applications, including human and veterinary diagnostics. Established in 2009 and headquartered in Sharnbrook, United Kingdom, the company designs, manufactures, and supplies diagnostic tests and accompanying readers. AgPlus Diagnostics employs an electrochemical reader and measurement system that enables personalized healthcare by delivering rapid diagnostic results based on individual biomarker profiles. This technology allows healthcare providers to make critical treatment decisions in a matter of minutes, enhancing the efficiency of patient care.
DIOSyn Vax (Digitally designed, Immune Optimised Selected and Synthesized Vaccines) is new technology that will significantly accelerate vaccine development and achieve dramatic improvements to the protection against emerging and re-emerging pathogens.
Reflection Therapeutics is developing cell therapy technology against neuroinflammation across the board.
ExplantLab is an independent research organization located in Newcastle upon Tyne, United Kingdom. The company focuses on exploring the connections between patient genetics and the design, manufacture, and performance of medical devices. By integrating genetic insights into its research, ExplantLab aims to enhance the effectiveness and safety of medical devices, ultimately improving the quality of life for patients.
Illuminum Greenhouses is an Agri-Tech greenhouse and drip installation company in Kenya working with smallholder farmers to improve productivity and increase efficiency through the use of new modern technologies while bundling up other services to ensure smallholder farmers access a turn key solution.
Naturbeads, a company working to manufacture a replacement ato the ocean-polluting microbeads that, despite initial bans in “rinse-off” cosmetics, are found in many personal and home care products and paints. Naturbeads manufacture a biodegradable alternative to plastic microbeads that could reduce micro plastic pollution in the oceans. The technology to create the cellulose microbeads was developed at the University of Bath by Professors Janet Scott and Davide Mattia from the Centre for Sustainable Chemical Technologies in 2017
Albotherm specializes in developing and manufacturing innovative passive cooling polymer coatings aimed at addressing climate change and its effects. The company's core technology is a smart transitioning coating that regulates surface temperatures without requiring any energy input. This coating reversibly changes from clear to white when temperatures exceed a specified trigger point, effectively reflecting unwanted light to mitigate overheating. This unique capability enables a range of industries to enhance thermal management in their structures and surfaces, contributing to energy efficiency and climate resilience.
Symbiosis Pharmaceutical Services was established in 2011 in response to increasing global demand for niche, sterile manufacturing specialists that could satisfy product supply needs for clinical trials.
We created our purpose-built facility in Stirling, Scotland, specifically designed with biologic and small molecule production capabilities in mind to support biotech and speciality pharmaceutical companies worldwide that require small-scale injectable products.
Differing from most CMOs, from the day our operations commenced we offered rapid access to manufacturing slots and quick release of drug products to ensure tight timelines are successfully met. Naturally, this has been a real hit with our clients.
Cyted focuses on providing digital diagnostic infrastructure to drive the earlier detection of disease. Our technologies use artificial intelligence and novel biomarkers to unlock clinical insight and improve patient outcomes. Cyted's mission is to revolutionise diagnostic methods to build a world where disease is prevented rather than treated.
Lunac Therapeutics
Grant in 2019
Lunac Therapeutics is a UK-based drug discovery company.
Sense Biodetection Limited is a molecular diagnostics company based in Abingdon, United Kingdom, established in 2013. The company specializes in developing innovative, user-centered, handheld diagnostic tests aimed at enhancing healthcare decisions, particularly in the fields of infections and oncology. Its flagship product, True Point-of-Care, serves as a clinical diagnostic tool that empowers users to make informed treatment decisions in a decentralized healthcare environment. By employing advanced molecular methods, including polymerase chain reaction (PCR) technology, Sense Biodetection's equipment allows clinics and medical professionals to detect infections promptly and effectively, facilitating immediate treatment options.
high expertise in the designing and testing of self-assembling peptides providing different benefits when culturing adherent cells in vitro.
Ixaka is a regenerative medicine company focused on developing advanced cell-based therapeutics aimed at treating serious diseases that lack effective existing therapies. The company is actively conducting clinical trials for its cellular therapies, with the goal of obtaining marketing authorization in Europe, the United States, and other global markets. Ixaka's approach is grounded in a deep understanding of the fundamental science behind cell therapies. Collaborating with the Andalusian Health Authority and the Andalusian Initiative of Advanced Therapies, Ixaka is working to expand its portfolio of cell therapies to address additional indications with significant unmet medical needs.
Atelerix Limited provides storage and transportation of cells and tissues at room temperature. The company provides suspended cells, planted cells, and tissues. It also discovers and tests new drugs, develops cell therapies, and stores stem cells. The company was founded in 2006 and is based in Cambridge, United Kingdom.
Naturbeads, a company working to manufacture a replacement ato the ocean-polluting microbeads that, despite initial bans in “rinse-off” cosmetics, are found in many personal and home care products and paints. Naturbeads manufacture a biodegradable alternative to plastic microbeads that could reduce micro plastic pollution in the oceans. The technology to create the cellulose microbeads was developed at the University of Bath by Professors Janet Scott and Davide Mattia from the Centre for Sustainable Chemical Technologies in 2017
Entocycle Ltd is a London-based company that specializes in producing insect-based protein for animal feed. Founded in 2014, it raises black soldier flies in an automated system designed to monitor their development and environmental conditions. By utilizing food waste from farms, factories, and the catering industry, Entocycle effectively converts organic waste into sustainable protein biomass. This approach not only provides a cost-effective alternative to traditional feed sources like soymeal and fishmeal but also addresses environmental concerns associated with conventional agriculture. The company's technology enables efficient vertical farming, allowing for large-scale production of protein with significantly reduced land and water usage. Entocycle serves various sectors, including feed suppliers, retailers, and the agricultural industry, promoting a more sustainable and resource-efficient method of livestock feeding.
Freeline Therapeutics is a clinical-stage biotechnology company focused on developing liver-directed gene therapies for bleeding disorders and other diseases. Based in Stevenage, United Kingdom, Freeline's lead product candidate, FLT180a, is undergoing Phase 1/2 clinical trials aimed at treating moderate to severe hemophilia B. The company's pipeline also includes FLT190, which is in dose-escalating Phase 1/2 trials for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A. Freeline utilizes a next-generation proprietary adeno-associated virus (AAV) vector platform, enhancing its potential for systemic gene therapy applications. Since its founding in 2015, the company has been dedicated to advancing innovative treatments in the field of gene therapy.
The Cell and Gene Therapy Catapult is a centre of excellence in innovation, with the core purpose of building a world-leading cell and gene therapy sector in the UK as a key part of a global industry. Supported by Innovate UK, their mission is to drive the growth of the industry by helping cell and gene therapy organisations across the world translate early stage research into commercially viable and investable therapies. They are based on the 12th floor of Guy’s Hospital in central London, with over 120 cell and gene therapy experts, state-of-the art development and viral vector laboratories. They are also building a £55m large-scale GMP manufacturing centre to help bring cell and gene therapies to market in the UK and internationally.
Symbiosis Pharmaceutical Services was established in 2011 in response to increasing global demand for niche, sterile manufacturing specialists that could satisfy product supply needs for clinical trials.
We created our purpose-built facility in Stirling, Scotland, specifically designed with biologic and small molecule production capabilities in mind to support biotech and speciality pharmaceutical companies worldwide that require small-scale injectable products.
Differing from most CMOs, from the day our operations commenced we offered rapid access to manufacturing slots and quick release of drug products to ensure tight timelines are successfully met. Naturally, this has been a real hit with our clients.
Aglaris is developing an automated cell culture bioreactor for the mass production of human stem cells. Aglaris produces equipment to ensure cell and tissue culture is an easy, problem-free task. By automating and controlling the cell culture processes, we can obtain cells and tissues with sufficient quality to revitalize regenerative medicine and cell therapies. The technology used by our equipment is unique and is protected by international patents.
Nanna Therapeutics is a drug discovery company addressing age-related diseases for which others are failing to provide effective treatments. These include mitochondrial, neurodegenerative, cardiovascular or metabolic, joint or tissue disease as well as cancer. Nanna Therapeutics are targeting fundamental cellular processes to create drugs to treat age-related diseases and improve longevity. Such drugs include those to combat debilitating neurodegenerative, inflammatory, cardiovascular and metabolic diseases as well as many cancers. With a strong focus on mitochondria, the energy source in every cell, we can target the fundamental causes of many age-related diseases. Through this approach we can also address debilitating, life-limiting mitochondrial diseases for which there are currently few effective therapies. Nanna Therapeutics has developed a tightly integrated set of proprietary technologies that radically disrupt current methods of creating new medicines. This Totally Integrated Medicines Engine (TIME) has been devised to answer the needs of drug discovery and development scientists utilising the best in 21st century technologies of microfluidics, nanofabrication and artificial intelligence.
IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.
DJS Antibodies Ltd, founded in 2014 and based in Bicester, United Kingdom, specializes in the design and discovery of innovative therapeutic monoclonal antibodies targeting G-protein-coupled receptors (GPCRs). The company is focused on addressing significant unmet medical needs through the development of new medicines, an inherently challenging process often hindered by traditional methodologies. DJS Antibodies utilizes a breakthrough technology that enhances the success rate of discovering lead antibodies, a process that has garnered early support from Johnson & Johnson. This approach has facilitated the advancement of lead programs aimed at treating cancer and kidney disease, positioning DJS Antibodies as a leader in the field of drug development.
Evox Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing exosome-based therapeutics for the treatment of severe diseases. Founded in 2016, the company leverages its proprietary technology to harness and engineer extracellular vesicles, known as exosomes, for the targeted delivery of nucleic acids and proteins. This innovative approach aims to enhance drug delivery to challenging areas, such as the brain and central nervous system, where conventional therapies often fall short. Evox’s mission is to improve human health by creating novel therapeutics that address significant medical needs, particularly for conditions with limited treatment options. The company has built a comprehensive intellectual property portfolio and is backed by prominent life sciences venture capital groups, positioning it as a leader in the emerging field of exosome-based drug delivery.
Breedr is a productivity and marketing platform that’s transforming the livestock supply-chain.
Brilliant Planet is unlocking the power of algae as an affordable method of permanently and quantifiably sequestering carbon at the gigaton scale. The company's innovative process enables vast quantities of microalgae to grow in open-air pond-based systems on coastal desert land.
Bionema is a leading biopesticide product testing and technology development company, specialising in chemical-free, organic crop protection. Research is focused on the development of natural products to protect crops from insect damage, reducing the use of synthetic pesticides, enhancing food security and increasing crop yields. Bionema supplies specialist bio-control products to the horticulture, turf and amenity and forestry sectors, providing training aimed at increasing the product efficacy.
Orbit Discovery Ltd. is a peptide display technology company based in Oxford, United Kingdom, founded in 2015. The company specializes in identifying peptide drugs aimed at treating chronic diseases by leveraging its innovative in vitro display technology. This technology utilizes small beads to connect randomized peptide sequences with their corresponding DNA, facilitating the screening of peptides for various disease types. Orbit Discovery focuses on developing a screening platform that identifies potential peptide drug candidates for both internal drug discovery programs and collaborative research initiatives. The company’s platform offers a means to discover and optimize novel, biologically relevant peptides, capitalizing on the unique properties of peptides that combine the specificity and efficacy of larger biologic molecules with the advantages of smaller molecules, such as reduced dosing and simpler manufacturing processes. This approach aims to enhance the discovery and development of peptide-based therapeutics.
Roslin Cells is the parent company of Roslin Cell Therapies. Based in Edinburgh, UK Roslin Cell Therapies has a wealth of expertise, capabilities and industry recognition in process translation to GMP, development, optimization, scale up and the GMP manufacture of Cell Therapy and Advanced Therapy Medicinal Products (ATMPs).
PepGen is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing the delivery of nucleic acid therapeutics, particularly antisense oligonucleotides. Established in 2018, PepGen aims to enhance the clinical efficacy of these therapeutics through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. This innovative technology employs engineered peptides designed for optimized tissue penetration, cellular uptake, and nuclear delivery, enabling effective transport of oligonucleotides to various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. By leveraging its drug delivery capabilities, PepGen seeks to transform the treatment landscape for severe neuromuscular and neurological diseases.
BIOS Health is a company based in Cambridge, United Kingdom, that specializes in developing a neural interface platform aimed at treating chronic health conditions. Founded in 2015, BIOS integrates advances in hardware, big data, and machine learning to create solutions that decode and encode neural signals from the body. The company also focuses on the development of prosthetic connectors, which standardize the connection between bionic devices and the body’s neural and soft-tissue systems. These implanted medical devices are designed to link nerve activity to specific conditions, facilitating precise communication and control for patients using prosthetics. BIOS operates an additional research and development office in Montreal, Canada.
RoslinCT is a prominent UK-based contract development and manufacturing organization specializing in cell therapy. The company offers a range of services tailored for organizations developing cell-based therapeutic products, including cell and gene therapy development, tissue procurement, and cryopreservation studies. Additionally, RoslinCT conducts pre-clinical studies and analytical development, ensuring that clients can deliver compliant, sustainable, and affordable therapies. Through its expertise, RoslinCT supports the advancement of innovative treatments in the field of regenerative medicine.
STORM Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Founded in 2015 and formerly known as Iceni Therapeutics Limited, the company utilizes a drug discovery and RNA analytics platform to identify novel targets and first-in-class drug candidates. By modulating RNA-modifying enzymes, STORM Therapeutics aims to address a range of diseases, including oncology, inflammation, viral infections, and central nervous system disorders. The company's innovative approach seeks to provide physicians with effective therapies targeting RNA epigenetic mechanisms.
Ubiquigent Limited is a biotechnology company based in Dundee, United Kingdom, specializing in the development and supply of high-quality reagents, kits, and drug discovery services. Founded in 2009, Ubiquigent focuses on protein degradation, particularly through the innovation of deubiquitylase (DUB) enzyme inhibitors. The company caters to the life science research community by providing drug discovery assay development and compound profiling services, targeting the ubiquitin and ubiquitin-like signaling systems. Ubiquigent collaborates with academic researchers and pharmaceutical scientists to advance drug discovery related to DUB modulators, which hold promise for addressing significant therapeutic needs. Additionally, the company is building a strong intellectual property portfolio that includes inhibitors and compounds aimed at enhancing drug development initiatives.
Almac Group is a prominent contract development and manufacturing organization based in Craigavon, United Kingdom, specializing in a comprehensive array of services for the pharmaceutical and biotech sectors. With over 40 years of organic growth, the company employs more than 4,500 skilled professionals and operates facilities in the UK, Ireland, the United States, and Asia. Almac Group's offerings encompass research and development, biomarker discovery and development, active pharmaceutical ingredient (API) manufacture, formulation development, clinical trial supply, and companion diagnostic development. The group also includes Almac Diagnostics, which focuses on biomarker discovery and validation, providing services such as bioinformatics solutions and genomic analyses. Additionally, Almac Discovery is dedicated to oncology, concentrating on innovative cancer treatment approaches during the discovery and preclinical stages. Through continuous investment in state-of-the-art technology and services, Almac Group supports clients throughout the entire biopharmaceutical product lifecycle, from preclinical development to commercialization.
Phico Therapeutics Limited operates as a biotechnology company that primarily focuses on developing antibiotics to overcome antibacterial resistance. Its SASPject platform delivers anti-bacterial proteins, such as small acid-soluble spore proteins to selected bacterial species using targetable non-delivery vehicles. The company’s portfolio includes SASPject PT3, an antibiotic against Pseudomonas aeruginosa; SASPject PT4 and SASPject PT5 for systemic use against Klebsiella pneumonia and Escherichia coli; and SASPject PT1.2 that targets Staphylococcus aureus. Phico Therapeutics Limited was incorporated in 2000 and is based in Bourn, United Kingdom.
Bioinduction is a developer of neuromodulation devices aimed at treating chronic pain and various neurological disorders. The company specializes in a deep brain stimulation platform that is both faster and simpler than traditional methods. Its innovative products include a skull-mounted deep brain stimulator, which features advanced capabilities such as neural recording and target steering. This design enhances the productivity of surgical teams and improves patient comfort by utilizing a unique skull location, differentiating Bioinduction’s offerings from conventional deep brain stimulation devices.
Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, established in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. By employing novel techniques, Evonetix aims to synthesize DNA with higher accuracy and scale, which enhances accessibility for researchers. This platform enables scientists to utilize synthetic biology on a previously unattainable scale, fundamentally changing how DNA is accessed, produced, and utilized for gene synthesis. The engineering team at Evonetix boasts extensive experience in creating high-integrity automated systems, bringing together a diverse range of expertise from various scientific and engineering disciplines to support its mission.
Arecor Limited is a biopharmaceutical company based in Cambridge, United Kingdom, specializing in the development of innovative stabilization technology solutions for pharmaceutical and biotech firms. The company partners with these organizations to enhance the commercial value and utility of proteins used in various applications, including vaccines, therapeutic proteins, and treatments for complex diseases. Arecor focuses on developing products for areas such as diabetes, oncology, immunology, and infectious diseases, working to reformulate existing therapies to improve their efficacy and ease of use. Its innovative formulation technology enables high concentrations of antibodies for at-home self-administration and stable liquid formulations for biological therapies. Arecor also addresses challenges related to protein degradation and stability, particularly in the formulation of growth hormones and vaccines. Founded in 2006, Arecor operates primarily in the UK and has a global reach, collaborating with leading pharmaceutical and biotech companies to deliver enhanced therapeutic solutions.
Beta Bugs is a biotechnology company specializing in the development of enhanced insect strains for the insect farming industry. By focusing on the genetic foundations of insects, particularly the black soldier fly, the company aims to create high-performance breeds that serve as a sustainable protein source for animal feed. These optimized strains convert food waste into high-quality protein, offering a viable alternative to traditional feed sources like soymeal and fishmeal. This innovation not only supports the profitability of the insect farming sector but also promotes environmentally sustainable practices by reducing reliance on conventional protein sources in livestock, aquaculture, and pet feed.
Glialign specializes in regenerative technologies aimed at enhancing peripheral nerve repair. The company is developing a novel cell therapy that serves as a living nerve growth guide, designed to replace traditional nerve grafts, which often require harvesting nerves from other body parts. Current treatments for peripheral nerve injuries are only effective in less than half of the cases, highlighting the need for more reliable solutions. Glialign's approach provides an off-the-shelf alternative, enabling healthcare providers to facilitate nerve regeneration and improve functional recovery for patients suffering from nerve injuries.
Sentinel Oncology Limited, a drug discovery company, develops and commercializes therapeutics to treat cancer. The company develops small molecule approaches to target the microenvironment of solid tumors. Its R&D programs pipeline includes Checkpoint Kinase 1, a protein kinase that activates in response to DNA damage and DNA replication stress; and an approach to treat metastatic breast cancer by developing a drug that inhibits S6K1 and offers treatment options for patients. The company was founded in 2005 and is based in Cambridge, United Kingdom.
NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system.The company's small molecule therapies target genetic mechanisms in order to create neoantigen which is known to stimulate the immune system and potentially be a weak spot in a tumor cell's defense mechanisms, enabling cancer patients to get treated and achieve improved clinical outcomes.
Vitamica was established in early 2018 as a spin-out company from the University of Bristol. Taking optical technology from the School of Physics, the new company is beginning its journey towards commercialisation of a rapid and novel diagnostic method that has high potential for use in antimicrobial susceptibility testing. With a growing IP portfolio and an active approach to identifying opportunities in healthcare, veterinary and pharma sectors, Vitamica fully intends to make its mark as another successful company to originate from the University of Bristol.
MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing a novel class of anti-infective medicines derived from DNA Minor Groove Binders (MGB). Established in 2009, the company is dedicated to creating small molecule antibacterial agents effective against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation for the treatment of Clostridium difficile associated disease. By targeting bacteria through a unique mode of action, MGB Biopharma aims to address the challenge of antibiotic resistance, offering healthcare providers more effective treatment options for bacterial infections. The experienced team at MGB Biopharma leverages expertise from the pharmaceutical and biotechnology sectors to drive its innovative research and development efforts.
Symbiosis Pharmaceutical Services was established in 2011 in response to increasing global demand for niche, sterile manufacturing specialists that could satisfy product supply needs for clinical trials.
We created our purpose-built facility in Stirling, Scotland, specifically designed with biologic and small molecule production capabilities in mind to support biotech and speciality pharmaceutical companies worldwide that require small-scale injectable products.
Differing from most CMOs, from the day our operations commenced we offered rapid access to manufacturing slots and quick release of drug products to ensure tight timelines are successfully met. Naturally, this has been a real hit with our clients.
Eagle Genomics Ltd. specializes in providing data management and analysis solutions for the healthcare, pharmaceutical, biotech, and personal care sectors. Founded in 2008 and based in Cambridge, United Kingdom, with additional offices in the United States, Germany, and India, the company focuses on the management and analysis of genomic data, particularly through next-generation sequencing technologies. Its services encompass NGS data management, analysis, visualization, biomarker discovery, and custom software development. The company also offers pipeline design services and a web-based platform, ElasticAP, for managing life sciences research and development data in the cloud. With a unique blend of expertise in biology, bioinformatics, data science, and software engineering, Eagle Genomics helps clients in drug development, personal hygiene, and agri-tech industries maximize the value of their research and development data, addressing challenges associated with the increasing volume of life sciences data.
Domainex Ltd is a contract research company that was established in 2001 and operates from Cambridge UK. In May 2007 Domainex merged with NCE Discovery to form a new integrated company with capabilities in biology and chemistry.
Service division offers technologies designed to clone and express challenging genes to give high-quality recombinant protein displaying functional domains of the target. We also provide computational and medicinal chemistry for the design and synthesis of candidate drugs aimed at our customers' target proteins.
Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research, development and manufacture. Gene therapy is the treatment of disease by delivering therapeutic DNA into a patient’s cells. This can be either in vivo or ex vivo, the latter encompassing the field of cell therapy whereby genetically modified cells are put back into the body. Their pipeline of seven gene and cell therapy therapy products addresses diseases for which there is currently no treatment or that are inadequately treated today, including ocular and central nervous system disorders. Their product candidates have the potential to transform treatment landscapes. Their strategy is to develop their product candidates to their next value inflection points whilst continuing to build OXB Solutions into a valuable revenue-generating manufacturing and development services business.
Ixaka is a regenerative medicine company focused on developing advanced cell-based therapeutics aimed at treating serious diseases that lack effective existing therapies. The company is actively conducting clinical trials for its cellular therapies, with the goal of obtaining marketing authorization in Europe, the United States, and other global markets. Ixaka's approach is grounded in a deep understanding of the fundamental science behind cell therapies. Collaborating with the Andalusian Health Authority and the Andalusian Initiative of Advanced Therapies, Ixaka is working to expand its portfolio of cell therapies to address additional indications with significant unmet medical needs.
Cobra Biologics Limited specializes in contract manufacturing services for biologics and pharmaceuticals, catering to pre-clinical, clinical, and commercial supply needs. The company offers a comprehensive range of services, including cell line development, GMP cell banking, stability testing, protein characterization, and various analytical services. It focuses on producing mammalian and microbial proteins, along with cGMP virus services essential for gene therapy and vaccine production. Cobra Biologics also provides plasmid DNA services, encompassing both non-GMP and GMP processes, and has expertise in aseptic pharmaceutical manufacturing, freeze-drying, and injectable product filling. With facilities in Keele, United Kingdom, and Södertälje, Sweden, the company has built a strong reputation in the global life sciences sector, supporting the development and commercialization of drugs through a combination of integrated and stand-alone services. Founded in 1992 and formerly known as RecipharmCobra Biologics Limited, Cobra Biologics operates as a subsidiary of Cognate BioServices, Inc.
BioSystems Technology engages in the development of alternative research models. BioSystems Technology was founded by an infectious disease research fellow and a Professor of Molecular Pathogenicity based at the University of Exeter.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
HayBeeSee is introducing fundamental change to "agronomy" and farming best-practice utilising state-of-the-art robotics and AI. We are creating a novel robotics platform allowing large daily coverage as well as close proximity sensing and interaction for farmers. The world of agri-tech is fast moving towards precision agriculture & robotics, yet farmers today lack access to any real products that deliver quality data or impact on their farm at all. Meet the CropHopper®, world’s first robot designed for fast and efficient jumping across fields to scan crops, identify weeds (single leaf), aphids & other bugs, early signs of disease, tiller-count, plant count, grain-counts per head as well as to carry out mechanical weeding and spot spraying. Lightweight, jumping all season, even in growing crops. An integrated, full-season management strategy.
Touchlight Genetics Ltd. is a biotechnology company based in Leatherhead, United Kingdom, focused on DNA therapies and technology. Founded in 2008, the company has developed the proTL synthetic DNA platform, which enables the production of doggybone closed linear DNA without the need for bacterial fermentation. This innovative approach serves various applications including veterinary vaccines, monoclonal antibodies, gene therapy, allergy treatment, RNA interference therapies, and stem cell reprogramming. Touchlight has assembled a skilled team of scientists and drug development experts, led by founder and CEO Jonny Ohlson, who is supported by a dynamic management team. The company has formed strategic collaborations with prestigious academic institutions such as Imperial College London and the University of Pennsylvania, contributing to the advancement of its technologies and the establishment of therapeutic proof-of-principle.
DJS Antibodies Ltd, founded in 2014 and based in Bicester, United Kingdom, specializes in the design and discovery of innovative therapeutic monoclonal antibodies targeting G-protein-coupled receptors (GPCRs). The company is focused on addressing significant unmet medical needs through the development of new medicines, an inherently challenging process often hindered by traditional methodologies. DJS Antibodies utilizes a breakthrough technology that enhances the success rate of discovering lead antibodies, a process that has garnered early support from Johnson & Johnson. This approach has facilitated the advancement of lead programs aimed at treating cancer and kidney disease, positioning DJS Antibodies as a leader in the field of drug development.
CN Bio Innovations Ltd, based in Cambridge, United Kingdom, specializes in developing Organ-on-Chip devices aimed at enhancing preclinical drug testing for pharmaceutical and biotechnology companies. The company creates microphysiological systems and consumables that enable consumer goods and chemical firms to assess the toxicity and safety of novel compounds using in vitro studies across various biological processes, including oncology, infectious diseases, metabolism, and inflammation. Formerly known as Zyoxel Ltd, CN Bio is recognized for its proprietary LiverChip® platform, which features a full viral lifecycle model of hepatitis B, called Quantum-B®. This model is utilized in drug discovery and research partnerships with leading industry players. Collaborating with academic experts in bio-engineering and supported by grants from organizations such as the United States Defence Advanced Research Projects Agency and the UK Technology Strategy Board, CN Bio is committed to advancing next-generation organ-on-chip technologies to facilitate the development of innovative therapies that could improve global health outcomes.
CHAIN Biotechnology Ltd. is a biotechnology company that specializes in developing and utilizing Clostridium bacteria for various applications, leveraging recent advancements in synthetic biology and automation to enhance fermentation processes. The company focuses on producing chiral chemicals, which are essential for a variety of products such as nutraceuticals, personal healthcare items, pharmaceuticals, and fragrances. Among its key developments are 3-hydroxybutyrate, a versatile chiral molecule, and (R)-methyl-3HB, a precursor chemical for the glaucoma treatment dorzolamide. Additionally, CHAIN Biotechnology is exploring cost-effective fermentation methods using sugar as a substrate. The company's expertise encompasses microbiology, molecular biology tools, and microbial strain development. Founded in 2014 and headquartered in London, United Kingdom, CHAIN Biotechnology is also engaged in developing therapeutic compounds aimed at addressing chronic gut-related diseases through its innovative drug development platform.
Centauri Therapeutics is a UK-based biotechnology company dedicated to discovering and developing innovative molecules aimed at combating life-threatening diseases. The company utilizes its proprietary Alphamer technology, which involves chemically synthesized molecules that redirect naturally occurring antibodies to specific pathogens, enhancing the immune response against infections. Each Alphamer consists of two components: one binds to a cell-surface target on the pathogen, while the other presents specific epitopes that engage circulating antibodies. This approach has demonstrated the ability to trigger an immediate antibacterial immune response, effectively clearing infections. Centauri Therapeutics' flexible Chemistry Platform allows for the synthesis of these bifunctional molecules, which are applicable in treating various infectious diseases. Additionally, the company has formed a joint venture, Avvinity Therapeutics, with Horizon Discovery to advance immuno-oncology initiatives, combining Centauri's expertise in Alphamer technology with Horizon's capabilities in gene editing and oncology. Through collaborations in aptamer selection, drug discovery, chemistry, and immunology, Centauri Therapeutics aims to enhance its impact in the field of immunotherapy.
Activirosomes specializes in the development of innovative vaccines and virotherapies aimed at treating viral infections. Utilizing a unique active virosome technology, the company creates multivalent vaccines that target various diseases, including cancer, avian viruses, and Zika virus. Activirosomes focuses on ensuring that its products are not only effective but also safe and affordable, thereby addressing critical healthcare needs in the field of infectious diseases and oncology.
Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.
Axitan is a biotechnology company specializing in the development of a microalgae-production platform aimed at producing innovative and safe alternatives to conventional antibiotics in animal agriculture. By leveraging algal biotechnology, Axitan seeks to address significant challenges in the industry, including the need for sustainable and resource-efficient production methods. The company focuses on developing a library of endolysins and related products designed to target pathogens that have traditionally been managed through antibiotic supplements in animal feed. This approach not only enhances productivity and production yields but also promotes better animal welfare and environmental protection. Through its initiatives, Axitan strives to facilitate a cost-effective transition away from antibiotics in the livestock sector.
Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, specializing in the development of diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care environments. The company's flagship products include the io System, which detects infectious diseases such as chlamydia and MRSA, and Callisto, designed to accommodate various testing throughput requirements. Binx Health focuses on providing solutions for sexually transmitted infections and hospital-acquired infections. The company aims to enhance healthcare accessibility by delivering on-demand testing directly to consumers, utilizing its proprietary, desktop, PCR-based platforms and mobile offerings. Established in 2005, Binx Health has formed a strategic partnership with Sherlock Biosciences to further advance its innovative healthcare solutions.
Better Origin, founded in 2015 and headquartered in Cambridge, United Kingdom, focuses on sustainable food systems through innovative insect biomass conversion technology. The company has developed two main processes for feeding insects: Metamorphosis, which can generate thousands of tons of insect meals annually, and Genesis, a data-driven engineering solution. By utilizing a network of AI-powered mini-farms, Better Origin effectively transforms excess nutrients into essential nutrients, addressing inefficiencies in the food supply chain. This approach aims to create a more sustainable and resource-efficient future, farm by farm.
Eagle Genomics Ltd. specializes in providing data management and analysis solutions for the healthcare, pharmaceutical, biotech, and personal care sectors. Founded in 2008 and based in Cambridge, United Kingdom, with additional offices in the United States, Germany, and India, the company focuses on the management and analysis of genomic data, particularly through next-generation sequencing technologies. Its services encompass NGS data management, analysis, visualization, biomarker discovery, and custom software development. The company also offers pipeline design services and a web-based platform, ElasticAP, for managing life sciences research and development data in the cloud. With a unique blend of expertise in biology, bioinformatics, data science, and software engineering, Eagle Genomics helps clients in drug development, personal hygiene, and agri-tech industries maximize the value of their research and development data, addressing challenges associated with the increasing volume of life sciences data.
Sentinel Oncology Limited, a drug discovery company, develops and commercializes therapeutics to treat cancer. The company develops small molecule approaches to target the microenvironment of solid tumors. Its R&D programs pipeline includes Checkpoint Kinase 1, a protein kinase that activates in response to DNA damage and DNA replication stress; and an approach to treat metastatic breast cancer by developing a drug that inhibits S6K1 and offers treatment options for patients. The company was founded in 2005 and is based in Cambridge, United Kingdom.
Sphere Fluidics Limited is a life sciences company focused on developing innovative technologies for single-cell analysis and characterization. The company offers specialized cell analysis systems that facilitate the discovery of new cell strains and molecules, aiding scientists in screening for and isolating rare biological variants. Their products serve various applications, including research, therapeutic development, bioproduction, and diagnostics. By providing collaborative research and development services, Sphere Fluidics aims to help clients enhance efficiency, reduce costs, and accelerate advancements in biological and biopharmaceutical discovery.
Jellagen Pty Ltd, founded in 2013 and based in Pembroke Dock, United Kingdom, specializes in harvesting jellyfish to produce high-grade native collagen. This innovative Med-Tech company focuses on providing non-mammalian jellyfish collagen, which is essential for various applications in tissue engineering, regenerative medicine, stem cell research, and cell culture. Jellagen's products are designed to meet the needs of medicinal researchers by offering batch-to-batch consistency and versatility for both in-vitro and in-vivo applications. The company's collagen is available in solution or powder form, supporting in-house research and the development of new medical devices aimed at improving wound management and advancing tissue engineering techniques.
AgPlus Diagnostics Ltd. is a company specializing in the development of a diagnostic platform technology aimed at providing quantitative point-of-care products for various clinical applications, including human and veterinary diagnostics. Established in 2009 and headquartered in Sharnbrook, United Kingdom, the company designs, manufactures, and supplies diagnostic tests and accompanying readers. AgPlus Diagnostics employs an electrochemical reader and measurement system that enables personalized healthcare by delivering rapid diagnostic results based on individual biomarker profiles. This technology allows healthcare providers to make critical treatment decisions in a matter of minutes, enhancing the efficiency of patient care.
Plasticell is a biotechnology company focused on developing innovative therapeutics through advanced cell culture and drug discovery platforms. The company specializes in elucidating the biochemical mechanisms that regulate the proliferation and differentiation of stem cells, which are essential for tissue development and repair. By testing a wide range of cell culture variables, Plasticell aims to establish optimal laboratory protocols for various applications in cell biology, gene transduction, protein production, and drug screening. This approach enables researchers to create novel small molecule drugs that promote regenerative medicine and improve therapeutic outcomes.
Autifony Therapeutics Limited is a biotechnology company based in London, United Kingdom, focused on developing innovative medicines for hearing disorders, including hearing loss and tinnitus. Established in 2011, the company leverages a drug discovery platform aimed at addressing unmet medical needs in this area. In addition to its primary focus on hearing-related conditions, Autifony's platform is also designed to alleviate symptoms associated with central nervous system disorders such as schizophrenia, fragile X syndrome, and Alzheimer's disease. By concentrating on these conditions, Autifony Therapeutics aims to provide effective treatment options for patients suffering from a range of debilitating disorders.
Stemnovate Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. It specializes in providing innovative tools and technologies for drug screening and safety testing. The company offers a range of products, including induced pluripotent stem cells, primary human and multispecies cells, and a comprehensive cell culture and analysis package. Stemnovate's project, "Liver on chip," focuses on liver toxicity testing and incorporates advanced techniques in cellular reprogramming and organ-on-chip technology. The company also provides services such as cell reprogramming, differentiation, and application development. Its clientele includes pharmacists, contract research organizations, small to medium enterprises, and academic institutions, enabling researchers to overcome challenges associated with traditional mammalian cell lines in drug discovery.
LIFNano Therapeutics was founded in 2013 as a spin-out from the University of Cambridge, progressing to a clinical stage Nano-Bio-Med company specifically focused on targeted delivery of the biologic, Leukaemia Inhibitory Factor (LIF)..